Vote Scores
Filings read through

Akero Therapeutics, Inc.: how funds voted at the meeting of 2 Dec 2025

Meeting
Season
year to 30 June 2026
Filers reporting
370
Ballot items
4

370 filers on Form N-PX reported votes at the Akero Therapeutics, Inc. meeting of 2 Dec 2025. The records fall into 4 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2026. Filings read through . How the figures are made

The ballot

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

  1. Item 1: Advisory vote on executive pay (say-on-pay)

    6 vote records from 4 filers. 1 of the 3 filers that marked the item voted against management. 1 filer gave no management mark.

  2. Item 2: Advisory vote on pay tied to a merger or sale

    537 vote records from 366 filers. 34 of the 338 filers that marked the item voted against management. 28 filers gave no management mark.

    • Positions of 44 fund families
    • For 39
    • Against 5
    • Against management 5
  3. Item 3: EXTRAORDINARY TRANSACTIONS: management items

    The company's items in this category are shown together, because filers word and number them differently.

    189 vote records from 95 filers. 0 of the 94 filers that marked the item voted against management. 1 filer gave no management mark.

    • Positions of 37 fund families
    • For 37
  4. Item 4: CORPORATE GOVERNANCE: management items

    The company's items in this category are shown together, because filers word and number them differently.

    243 vote records from 112 filers. 8 of the 112 filers that marked the item voted against management.

    • Positions of 39 fund families
    • For 36
    • Against 3
    • Against management 3

Positions of the fund families

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Akero Therapeutics, Inc., meeting of 2 Dec 2025Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund family2. Merger pay
AllianceBernsteinAgainst, against management
AllspringFor
American CenturyFor
BairdFor
BlackRock and iSharesFor
BNY MellonFor
Brighthouse FundsFor
Charles SchwabFor
Columbia ThreadneedleFor
DimensionalFor
DWSFor
EquitableFor
FidelityFor
First TrustFor
Franklin TempletonFor
Global XFor
Goldman SachsFor
Guggenheim and RydexFor
Hartford FundsFor
InvescoFor
J.P. MorganAgainst, against management
Jackson National fundsFor
Janus HendersonFor
John Hancock and ManulifeFor
Lincoln FinancialFor
Macquarie and Delaware FundsFor
MassMutualFor
Morgan Stanley, Eaton Vance and CalvertFor
NationwideFor
Natixis and Loomis SaylesFor
Neuberger BermanFor
Northern Trust and FlexSharesAgainst, against management
Nuveen and TIAAAgainst, against management
Pacific Life fundsFor
PGIM and PrudentialFor
PrincipalFor
ProShares and ProFundsFor
Russell InvestmentsFor
SEIFor
State Street and SPDRFor
T. Rowe PriceFor
VanguardFor
Victory CapitalFor
VoyaAgainst, against management

Questions

How many filers reported votes at the Akero Therapeutics, Inc. meeting?
370 Form N-PX filers reported votes at the meeting of 2 Dec 2025. On say-on-pay, 1 of 3 filers that marked the item voted against management (33.3%).
Is this the result of the meeting?
No. The page counts the filers that report on Form N-PX, and the shares they reported. Akero Therapeutics, Inc. reports the result of a vote on Form 8-K.
Why does the page show counts only for director elections?
A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Akero Therapeutics, Inc. with a meeting date within three days of 2 Dec 2025. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .